AUTHORS
Olisaemeka Ogbue, MBBS, Jun Ma2, Shulan Tian, PhD3, Pankaj Pradeep4, Duc Tran, PhD5, Terra Lasho, PhD6, Abhishek Avinash Mangaonkar, MBBS7, Matthew J Koster, MD8, Mrinal M. Patnaik, MD, MBBS9, Aref Al-Kali, M.D.10, Kelly Bolton, MD, PhD11, Tariq Kewan, MD12
AFFILIATIONS
1 Mayo Clinic, Rochester, Minnesota, United States
2 Mayo Clinic, Rochester, Minnesota, United States
3 Mayo Clinic, Rochester, Minnesota, United States
4 Mayo Clinic, Rochester, Minnesota, United States
5 Washington University School of Medicine, St. Louis, United States
6 Mayo Clinic, Rochester, Minnesota, United States
7 Mayo Clinic, Rochester, Minnesota, United States
8 Mayo Clinic, Rochester, Minnesota, United States
9 Mayo Clinic, Rochester, Minnesota, United States
10 Mayo Clinic, Rochester, Minnesota, United States
11 Washington University School of Medicine, St. Louis, United States
12 Mayo Clinic, Rochester, Minnesota, United States
ABSTRACT
Introduction
Chronic inflammation is increasingly recognized as a driver of clonal hematopoiesis (CH), with sustained cytokine signaling and recurrent stress hematopoiesis promoting the selective expansion of mutant hematopoietic clones and contributing to myeloid neoplasia (MN). Pathogenic/likely pathogenic (P/LP) germline (GL) variants affecting inflammatory pathways underlie several inherited inflammatory disorders, yet their relationship with CH remains poorly understood. We hypothesized that carriers of P/LP GL variants in inflammatory pathway genes have an increased prevalence of CH and enrichment of specific CH driver mutations compared with non-carriers.
Methods
Whole-genome sequencing (WGS) from the All of Us Program was used to identify rare (gnomAD MAF <0.001) germline (GL) variants in 86 prespecified genes involved in inflammasome, innate immune, cytokine signaling, immune regulatory, and cytotoxic lymphocyte pathways. Variants were classified according to American College of Medical Genetics and Genomics (ACMG) criteria, and only pathogenic/likely pathogenic (P/LP) variants were included. The analysis cohort consisted of individuals harboring P/LP variants in these genes, and rheumatologic diagnoses were subsequently identified using ICD-10 codes. CH was detected from blood-derived WGS (variant allele frequency ≥2%) using a previously validated somatic variant-calling pipeline (PMID: 36652671). Because bone marrow evaluation was unavailable, occult MN could not be definitively excluded. CH prevalence and driver-gene distribution were compared between P/LP variant carriers and 1:1 matched non-carriers matched for age, sex, ancestry, and smoking history. Associations between rheumatologic disease, GL variant status, and CH were evaluated using logistic regression.
Results
A total of 7,998 individuals harboring P/LP GL inflammatory pathway variants were identified, of whom 1,268 (16%) carried more than one P/LP variant. Among carriers, the most common rheumatologic diagnoses were fibromyalgia (36.5%), rheumatoid arthritis (RA) (33.6%), Sjögren syndrome (13.8%), systemic lupus erythematosus (SLE) (12.7%), and connective tissue disease (CTD) (8.3%). The most frequent P/LP GL variants occurred in STXBP2 (7.2%), UNC13D (6.9%), LRBA (6.3%), TYK2 (5.8%), LPIN2 (5.4%), and AIRE (4.6%); NLRP3 and ADA2 variants were identified in 2.3% and 2.1% of participants, respectively.
Compared with matched non-carriers, CH prevalence was significantly higher among carriers (7.9% vs. 5.7%; P<0.001). This increase was primarily driven by higher frequencies of DNMT3A (3.6% vs. 2.7%; P=0.002; median VAF 13.1% [IQR 9.7–20.2]), PPM1D (0.4% vs. 0.2%; P=0.009; median VAF 12.8% [IQR 10.5–23.8]), and STAT3 (0.6% vs. 0%; P<0.001; median VAF 14.0% [IQR 10.4–17.5]) mutations, whereas TET2 (1.2% vs. 0.9%; P=0.124) and ASXL1 (0.3% vs. 0.3%; P=1.00) frequencies were similar between groups.
Among carriers of P/LP GL variants, CH prevalence varied across rheumatologic diseases, ranging from 5.1% in CTD to 12.3% in polymyalgia rheumatica (PMR). The highest frequencies were observed in PMR (12.3%), giant cell arteritis (GCA) (11.5%), and vasculitis (9.2%). On univariable logistic regression, PMR (OR 1.9, P<0.001), GCA (OR 1.7, P=0.025), and RA (OR 1.2, P=0.031) were associated with increased odds of CH, whereas fibromyalgia (OR 0.6, P<0.001), CTD (OR 0.7, P=0.028), and SLE (OR 0.7, P=0.031) were associated with lower odds.
CH prevalence varied across common P/LP GL variant groups, ranging from 4.5% among RNASEH2B carriers to 10.3% among ADA2 carriers. Despite this variation, no individual GL variant remained independently associated with overall CH after logistic regression. Across all GL variant groups, DNMT3A and TET2 were the predominant CH driver genes. The only gene-specific association identified was an increased prevalence of TET2-mutant CH among IFIH1 carriers (2.9% vs. 1.1%; OR 2.6, P=0.024)
Conclusions
Carriers of P/LP GL variants in inflammatory pathway genes exhibit a significantly higher prevalence of CH than matched controls, primarily driven by expansion of DNMT3A-, PPM1D-, and STAT3-mutant clones. These findings support an association between inherited inflammatory pathway dysfunction and CH and provide a rationale for future studies investigating GL–somatic interactions in inflammatory disease and MN.
DISCLOSURES
Olisaemeka Ogbue, MBBS: No relevant conflicts of interest to declare.